CTLA-4 blockade boosts the expansion of tumor-reactive CD8⁺ tumor-infiltrating lymphocytes in ovarian cancer.

ABSTRACT: Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) can induce durable complete tumor regression in patients with advanced melanoma. Efforts are currently underway to expand this treatment modality to other cancer types. In the microenvironment of ovarian cancer, the engagement of co-inhibitory immune checkpoint molecules such as CTLA-4 can lead to the inactivation of TILs. Thus, approaches that directly manipulate co-inhibitory pathways within the tumor microenvironment might improve the expansion of tumor-reactive TILs. The initial expansion of TILs for ACT from tumor fragments provides a window of opportunity to manipulate an intact tumor microenvironment and improve CD8⁺ T-cell output and TIL tumor reactivity. To exploit this, we used a CTLA-4-b

SUBMITTER: Friese C 

PROVIDER: S-EPMC7054305 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature